Literature DB >> 11702087

Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients.

N Srivastava1, M K Barthwal, P K Dalal, A K Agarwal, D Nag, R C Srimal, P K Seth, M Dikshit.   

Abstract

RATIONALE: Recent studies have suggested augmentation in the inflammatory response as well as involvement of nitric oxide (NO) in mood disorders. Polymorphonuclear leukocytes (PMN), NO and free radicals have been associated with inflammatory response; however, the status of NO in the PMN has not been investigated so far in schizophrenia patients.
OBJECTIVES: The present study was undertaken to investigate levels of nitrite (a metabolite of NO), malonaldehyde (MDA, lipid peroxidation product) and antioxidant enzymes such as superoxide dismutase (SOD), catalase and glutathione peroxidase (Gpx) in the PMN of schizophrenia patients.
METHODS: Patients with schizophrenia (n=62) were diagnosed according to DSM-IV and were free of anti-psychotic medications/ECT for at least 3 months. Mean age of the patients was 29.06+/-1.17 years, with a male to female ratio of 4:1, and mean duration of illness was 3.7+/-0.6 years. The control group consisted of 82 healthy subjects with a mean age of 37.0+/-1.26 and a male to female ratio of 5:1. PMN were isolated from the blood. Nitrite, MDA and antioxidant enzymes were estimated by standard biochemical techniques in the PMN of normal healthy controls and schizophrenia patients. Platelet and plasma nitrite levels were also estimated in controls and schizophrenia patients.
RESULTS: Nitrite content in the PMN was reduced to 68%, while plasma and platelet nitrite content in schizophrenia patients was not significantly changed in comparison to controls. Malonaldehyde (MDA) content in PMN was significantly augmented in schizophrenia patients but activity of SOD, catalase and Gpx remain unaltered.
CONCLUSION: Results obtained indicate a significant decrease in NO synthesis and an increase in MDA in the PMN of schizophrenia patients, while antioxidant enzyme activities were not altered in the PMN of schizophrenia patients. This suggests that the decrease in PMN NO synthesis by PMN might lead to oxidative stress in schizophrenia patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702087     DOI: 10.1007/s002130100860

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Epicatechin inhibits human plasma lipid peroxidation caused by haloperidol in vitro.

Authors:  Anna Dietrich-Muszalska; Bogdan Kontek; Beata Olas; Jolanta Rabe-Jabłońska
Journal:  Neurochem Res       Date:  2011-11-12       Impact factor: 3.996

2.  Nitric oxide synthase mediates the ability of darbepoetin alpha to improve the cognitive performance of STOP null mice.

Authors:  Kosuke Kajitani; Michael Thorne; Michel Samson; George S Robertson
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 3.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 4.  Viral infection, inflammation and schizophrenia.

Authors:  Rachel E Kneeland; S Hossein Fatemi
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-10       Impact factor: 5.067

5.  Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome.

Authors:  W Jordan; S Cohrs; D Degner; A Meier; A Rodenbeck; G Mayer; J Pilz; E Rüther; J Kornhuber; S Bleich
Journal:  J Neural Transm (Vienna)       Date:  2005-06-15       Impact factor: 3.575

Review 6.  Possible mechanisms of neurodegeneration in schizophrenia.

Authors:  Iván Pérez-Neri; Jesús Ramírez-Bermúdez; Sergio Montes; Camilo Ríos
Journal:  Neurochem Res       Date:  2006-09-28       Impact factor: 3.996

7.  Meta-analysis of oxidative stress in schizophrenia.

Authors:  Joshua Flatow; Peter Buckley; Brian J Miller
Journal:  Biol Psychiatry       Date:  2013-05-15       Impact factor: 13.382

Review 8.  Antioxidants as potential therapeutics for neuropsychiatric disorders.

Authors:  Chirayu D Pandya; Kristy R Howell; Anilkumar Pillai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-11-02       Impact factor: 5.067

9.  Plasma nitrate levels in deficit versus non-deficit forms of schizophrenia.

Authors:  Eiji Suzuki; Toshio Nakaki; Makoto Nakamura; Hitoshi Miyaoka
Journal:  J Psychiatry Neurosci       Date:  2003-07       Impact factor: 6.186

10.  Reduced antioxidant defense in early onset first-episode psychosis: a case-control study.

Authors:  Juan Antonio Micó; Maria Olga Rojas-Corrales; Juan Gibert-Rahola; Mara Parellada; Dolores Moreno; David Fraguas; Montserrat Graell; Javier Gil; Jon Irazusta; Josefina Castro-Fornieles; Cesar Soutullo; Celso Arango; Soraya Otero; Ana Navarro; Inmaculada Baeza; Mónica Martínez-Cengotitabengoa; Ana González-Pinto
Journal:  BMC Psychiatry       Date:  2011-02-14       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.